Breakthrough antibodies neutralize most known AIDS strains

Afp
Thursday 08 July 2010 19:00 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

US researchers have discovered two powerful antibodies that neutralize more than 90 percent of all known strains of the HIV virus in the lab, new research released Thursday showed.

NIH-led scientists discovered the antibodies known as VRCO1 and VRCO2 that prevent most HIV strains from infecting human cells. The find is a potential breakthrough for advancing HIV vaccine design, and antibody therapy for other diseases.

The authors, whose work is published in the July 9 issue of Science, also were able to demonstrate how one of these disease-fighting proteins gets the job done.

"The discovery of these exceptionally broadly neutralizing antibodies to HIV and the structural analysis that explains how they work are exciting advances that will accelerate our efforts to find a preventive HIV vaccine for global use," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.

"In addition, the technique the teams used to find the new antibodies represents a novel strategy that could be applied to vaccine design for many other infectious diseases," Fauci stressed in a statement.

The team of virologists found that the two antibodies were produced naturally and found in the blood of HIV-positive people.

They were able to isolate these antibodies using a new molecular device they developed. It zeroes in on specific cells that make antibodies against HIV. The device is an HIV protein scientists modified to react only with antibodies specific to the site where the virus binds to cells it infects.

Leading two research teams were NIAID scientists Peter Kwong, Ph.D., John Mascola, MD, and Gary Nabel, MD, Ph.D.

"We have used our knowledge of the structure of a virus - in this case, the outer surface of HIV - to refine molecular tools that pinpoint the vulnerable spot on the virus and guide us to antibodies that attach to this spot, blocking the virus from infecting cells," explained Nabel.

Mascola added that: "the antibodies attach to a virtually unchanging part of the virus, and this explains why they can neutralize such an extraordinary range of HIV strains."

js/mdl/fgf

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in